The FDA Circular (FC) Nos. 2020-012 and 2020-012-A were issued to provide DEU registration guidelines for selected drug products identified under the Philippine Society for Microbiology and Infectious Diseases (PSMID) Clinical Practice Guidelines (CPG) on COVID-19.
Due to the regular updates to the quarantine status of the different cities and municipalities and in the event that the imposed quarantine is lifted, the provisions of this Circular may still deemed be applicable and necessary by the public’s interest.
In view of the foregoing, the effectivity of FC Nos. 2020-012 and 2020-012-A shall be until 31 December 2020, subject for extension upon the review of this Office.
Read more:-> FDA Circular No.2020-012-B